Cargando…

Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population

Infants and young children represent an important but much understudied childhood cancer patient population. The pharmacokinetics and pharmacogenetics of the widely used anticancer prodrug cyclophosphamide were investigated in children <2 years of age. Concentrations of cyclophosphamide and selec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnett, Shelby, Errington, Julie, Sludden, Julieann, Jamieson, David, Poinsignon, Vianney, Paci, Angelo, Veal, Gareth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002238/ https://www.ncbi.nlm.nih.gov/pubmed/33809608 http://dx.doi.org/10.3390/ph14030272

Ejemplares similares

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma
por: Veal, Gareth J., et al.
Publicado: (2016)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer
por: Hill, Christopher R., et al.
Publicado: (2014)

Generation of evidence-based carboplatin dosing guidelines for neonates and infants
por: Barnett, Shelby, et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC
por: Ozbey, Agustos Cetin, et al.
Publicado: (2021)

The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review
por: Yalçin, Nadir, et al.
Publicado: (2022)

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2020)

Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients
por: Barnett, Shelby, et al.
Publicado: (2022)

Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations
por: Barnett, Shelby, et al.
Publicado: (2022)

Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence
por: White-Koning, Melanie, et al.
Publicado: (2018)

Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance
por: Nijstad, A. Laura, et al.
Publicado: (2022)

Physico-Chemical Stability of Busulfan in Injectable Solutions in Various Administration Packages
por: Houot, Mélanie, et al.
Publicado: (2013)

Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
por: Veal, Gareth J., et al.
Publicado: (2016)

Carboplatin therapeutic monitoring in preterm and full-term neonates
por: Veal, Gareth J., et al.
Publicado: (2015)

Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report
por: Barnett, Shelby, et al.
Publicado: (2023)

Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13-cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial
por: Veal, Gareth J., et al.
Publicado: (2021)

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
por: Brunet, Mercè, et al.
Publicado: (2022)

Ethanol Pharmacokinetics in Neonates and Infants
por: Marek, Elizabeth, et al.
Publicado: (2014)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Distribution and pharmacokinetics of cyclophosphamide in the rat.
por: Talha, M. R., et al.
Publicado: (1980)

Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
por: Teng, Renli
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
por: Yu, Meng, et al.
Publicado: (2018)

A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children
por: Nijstad, A. Laura, et al.
Publicado: (2022)

Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK
por: Errington, Julie, et al.
Publicado: (2016)

Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
por: Alvitigala, Bhawani Yasassri, et al.
Publicado: (2020)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals
por: Nwogu, Jacinta Nwamaka, et al.
Publicado: (2016)

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo
por: Hill, Christopher R., et al.
Publicado: (2013)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
por: Ward, Robert M., et al.
Publicado: (2013)

A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
por: Baietto, Lorena, et al.
Publicado: (2014)

Individualization of Mycophenolic Acid Therapy through Pharmacogenetic, Pharmacokinetic and Pharmacodynamic Testing
por: Winnicki, Wolfgang, et al.
Publicado: (2022)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women
por: Mutagonda, Ritah F., et al.
Publicado: (2017)

Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children
por: Li, Qian, et al.
Publicado: (2019)

Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants
por: Zhao, Yang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a86q6nh2tml9o8eejgi8f2smsa